Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11542248B2 · kind B2 · utility
3Cited by
25References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 7, 2018 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Sep 27, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.